​​Current cancer treatments, including existing immunotherapies, face two critical challenges: tumor heterogeneity and immunosuppressive microenvironments.

​

• Tumor Heterogeneity: Cancers often consist of a diverse range of mutated cells, making it difficult for therapies that target only a few antigens to eliminate the entire tumor.

• Immunosuppressive Tumor Microenvironments: Many solid and refractory cancers produce signals (e.g., TGF-β, IL-10) that weaken T cells or block them from infiltrating the tumor, limiting the efficacy of CAR-T, TCR-T, and vaccine-based therapies.

​​

At Pyrojas, we address these problems by developing personalized, rapid-response solutions that activate and sustain the immune system’s ability to detect and destroy cancer cells, even in hostile tumor microenvironments.